Cargando…
Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study
OBJECTIVES: It is not clear whether dopaminergic medication influences bruxism behaviour in patients with Parkinson’s disease (PD). Therefore, the aims are to investigate (i) the prevalence of possible (i.e., self-reported) bruxism (sleep and awake) in PD patients, and (ii) whether the use of dopami...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060196/ https://www.ncbi.nlm.nih.gov/pubmed/32918624 http://dx.doi.org/10.1007/s00784-020-03566-0 |
_version_ | 1783681311579308032 |
---|---|
author | Verhoeff, M. C. Koutris, M. van Selms, M. K. A. Brandwijk, A. N. Heres, M. S. Berendse, H. W. van Dijk, K. D. Lobbezoo, F. |
author_facet | Verhoeff, M. C. Koutris, M. van Selms, M. K. A. Brandwijk, A. N. Heres, M. S. Berendse, H. W. van Dijk, K. D. Lobbezoo, F. |
author_sort | Verhoeff, M. C. |
collection | PubMed |
description | OBJECTIVES: It is not clear whether dopaminergic medication influences bruxism behaviour in patients with Parkinson’s disease (PD). Therefore, the aims are to investigate (i) the prevalence of possible (i.e., self-reported) bruxism (sleep and awake) in PD patients, and (ii) whether the use of dopaminergic medication and other factors (viz., demographic characteristics, PD-related factors, and possible consequences of bruxism) are associated with possible bruxism (sleep or awake). MATERIALS AND METHODS: This study concerns a secondary analysis of an earlier published study. Three hundred ninety-five PD patients (67.9 ± 8.6 years of age; 58.7% males) were included. The levodopa equivalent daily dosage (LEDD) was used as a measure of the dopaminergic medication level. Subsequently, a logistic regression analysis was performed for the dependent variables ‘awake bruxism’ and ‘sleep bruxism’, with the following predictors: gender, age, LEDD, time since PD diagnosis, temporomandibular disorder (TMD) pain, jaw locks, and tooth wear. RESULTS: The prevalence of possible awake and sleep bruxism was 46.0% and 24.3%, respectively. Awake bruxism was associated with sleep bruxism (OR = 8.52; 95% CI 3.56–20.40), TMD pain (OR = 4.51; 95% CI 2.31–8.79), and tooth wear (OR = 1.87; 95% CI 1.02–3.43). Sleep bruxism was associated with tooth wear (OR = 12.49; 95% CI 4.97–31.38) and awake bruxism (OR = 9.48; 95% CI 4.24–21.19). Dopaminergic medication dose was not associated with awake bruxism (OR = 1.0; 95% CI 0.99–1.00) or sleep bruxism (OR = 1.0; 95% CI 0.99–1.00). CONCLUSION: Bruxism is a common condition in PD patients, but is not associated with the dopaminergic medication dose. CLINICAL RELEVANCE: (Oral) health care providers should be alerted about the possibility of sleep and awake bruxism activity in PD patients, along with this activity’s possible negative health outcomes (viz., TMD pain, tooth wear). |
format | Online Article Text |
id | pubmed-8060196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-80601962021-05-05 Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study Verhoeff, M. C. Koutris, M. van Selms, M. K. A. Brandwijk, A. N. Heres, M. S. Berendse, H. W. van Dijk, K. D. Lobbezoo, F. Clin Oral Investig Original Article OBJECTIVES: It is not clear whether dopaminergic medication influences bruxism behaviour in patients with Parkinson’s disease (PD). Therefore, the aims are to investigate (i) the prevalence of possible (i.e., self-reported) bruxism (sleep and awake) in PD patients, and (ii) whether the use of dopaminergic medication and other factors (viz., demographic characteristics, PD-related factors, and possible consequences of bruxism) are associated with possible bruxism (sleep or awake). MATERIALS AND METHODS: This study concerns a secondary analysis of an earlier published study. Three hundred ninety-five PD patients (67.9 ± 8.6 years of age; 58.7% males) were included. The levodopa equivalent daily dosage (LEDD) was used as a measure of the dopaminergic medication level. Subsequently, a logistic regression analysis was performed for the dependent variables ‘awake bruxism’ and ‘sleep bruxism’, with the following predictors: gender, age, LEDD, time since PD diagnosis, temporomandibular disorder (TMD) pain, jaw locks, and tooth wear. RESULTS: The prevalence of possible awake and sleep bruxism was 46.0% and 24.3%, respectively. Awake bruxism was associated with sleep bruxism (OR = 8.52; 95% CI 3.56–20.40), TMD pain (OR = 4.51; 95% CI 2.31–8.79), and tooth wear (OR = 1.87; 95% CI 1.02–3.43). Sleep bruxism was associated with tooth wear (OR = 12.49; 95% CI 4.97–31.38) and awake bruxism (OR = 9.48; 95% CI 4.24–21.19). Dopaminergic medication dose was not associated with awake bruxism (OR = 1.0; 95% CI 0.99–1.00) or sleep bruxism (OR = 1.0; 95% CI 0.99–1.00). CONCLUSION: Bruxism is a common condition in PD patients, but is not associated with the dopaminergic medication dose. CLINICAL RELEVANCE: (Oral) health care providers should be alerted about the possibility of sleep and awake bruxism activity in PD patients, along with this activity’s possible negative health outcomes (viz., TMD pain, tooth wear). Springer Berlin Heidelberg 2020-09-12 2021 /pmc/articles/PMC8060196/ /pubmed/32918624 http://dx.doi.org/10.1007/s00784-020-03566-0 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Verhoeff, M. C. Koutris, M. van Selms, M. K. A. Brandwijk, A. N. Heres, M. S. Berendse, H. W. van Dijk, K. D. Lobbezoo, F. Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study |
title | Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study |
title_full | Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study |
title_fullStr | Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study |
title_full_unstemmed | Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study |
title_short | Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study |
title_sort | is dopaminergic medication dose associated with self-reported bruxism in parkinson’s disease? a cross-sectional, questionnaire-based study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060196/ https://www.ncbi.nlm.nih.gov/pubmed/32918624 http://dx.doi.org/10.1007/s00784-020-03566-0 |
work_keys_str_mv | AT verhoeffmc isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy AT koutrism isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy AT vanselmsmka isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy AT brandwijkan isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy AT heresms isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy AT berendsehw isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy AT vandijkkd isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy AT lobbezoof isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy |